Liraglutide combination with sulfonylurea investigated for improved glycemic control in Type 2 Diabetes

Managing Type 2 Diabetes Mellitus (T2DM) often requires combination therapy to achieve optimal glycemic control and prevent complications. Sulfonylureas (SUs) are a common class of oral antidiabetic drugs that stimulate insulin secretion from pancreatic beta cells, but their use can be limited by risks of hypoglycemia and weight gain. Glucagon-like peptide-1 receptor (GLP-1R) agonists, like liraglutide, offer a different mechanism by enhancing glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and promoting satiety, often leading to weight loss and lower hypoglycemia risk. This trial aimed to assess if adding liraglutide could improve outcomes when combined with SU.

This Phase 3, randomized, double-blind, placebo-controlled clinical trial enrolled 400 subjects with Type 2 Diabetes in Japan. Participants were randomized to receive either liraglutide in combination with a sulfonylurea agent (SU) or placebo in combination with SU. The primary objective was to compare the effect on glycemic control, as assessed by HbA1c levels, after 24 weeks and 52 weeks of treatment. The study included an initial 24-week randomization period, followed by a 28-week extension period, totaling 52 weeks of observation for long-term efficacy.

This abstract describes the design and objectives of a Phase 3 randomized controlled trial investigating liraglutide in combination with sulfonylurea for Type 2 Diabetes. No specific results, such as changes in HbA1c or other glycemic parameters, are presented in this trial description. The study aimed to compare the effect on glycemic control, as assessed by HbA1c after 24 weeks and 52 weeks, between the combination therapy and sulfonylurea monotherapy. Therefore, no quantitative findings can be reported from this abstract, as it outlines the trial protocol rather than its outcomes. The trial was completed, but results are not detailed here.